AMSTERDAM, September 26 /PRNewswire/ --     Agendia BV, a world leader in the rapidly evolving field of cancer
molecular diagnostics, announces that it has joint the US-based Personalized
Medicine Coalition (PMC).

"The PMC is playing a key role in shaping the US public policy on
personalized medicine. We are very pleased to be a member of a group that
will dramatically impact the treatment of patients in the future. After we
got both our first IVDMIA product, MammaPrint(R), as well as our logistical
sampling and shipping procedure, RNARetain(R)(1), cleared by the FDA we
believe it is now time to actively participate in the discussion about the
implementation of personalized medicine in the US," said Dr. Bernhard Sixt,
CEO of Agendia BV.

Edward Abrahams, Executive Director of the PMC, welcomed the addition of
the Netherlands-based personalized medicine company: "We very much look
forward to Agendia's involvement in PMC's activities, in particular its
participation in our efforts to shape an appropriate regulatory pathway for
personalized medicine products."

About PMC

The Personalized medicine coalition was publicly launched in November
2004 by more than a dozen leading pharmaceutical, biotechnology, diagnostics
and information technology companies, along with major academic centres and
governmental agencies. An independent, non-profit group dedicated to
advancing the understanding and adoption of personalized medicine concepts
and products for the benefit of patients, it represents over 100 members. The
Coalition seeks to promote discussion and understanding that will lead to the
development of sound public policy on matters that affect the realization of
personalized medicine.

About Agendia

Agendia, located in Amsterdam, the Netherlands, is a world leader in gene
expression analysis-based diagnostics with three products on the market. The
company focuses on the development and commercialization of diagnostic tests
using tumor gene expression profiling. Agendia was the first company to
commercialize a prognostic test - MammaPrint(R) - that predicts the risk of
breast cancer recurrence. Its second microarray product, CupPrint(R)(2), is a
diagnostic test to identify the origin of a metastasis in a cancer type
called "Cancer of Unknown Primary". Agendia recently also presented its new
colon cancer prognosis profile, ColoPrint(R), which is currently undergoing
further validation.

Agendia maintains close ties with several leading academic centers to
develop state of the art diagnostic tests for cancer. Agendia also offers its
expertise to pharma companies focusing on development of highly effective
personalized drugs in the area of oncology.

(1) RNARetain(R) is a trademark of Asuragen Inc.

(2) CupPrint(R) is based on a license to the TUO database of AviaraDx
Inc.